Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture
Applied Microbiology and Biotechnology · 2024-12 · 108 (1)
DOI: 10.1007/s00253-024-13110-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 26.03.2024. Verfasst von George Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoglobulin G. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The pharmaceutical industry employs various strategies to improve cell productivity. These strategies include process intensification, culture media improvement, clonal selection, media supplementation and genetic engineering of cells. However, improved cell productivity has inherent risk of impacting product quality attributes (PQA). PQAs may affect the products’ efficacy via stability, bioavailability, or in vivo bioactivity. Variations in manufacturing process may introduce heterogeneity in the products by altering the type and extent of N-glycosylation, which is a PQA of therapeutic proteins. We investigated the effect of different cell densities representing increasing process intensification in a perfusion cell culture on the production of an IgG1-κ monoclonal antibody from a CHO-K1 cell line. This antibody is glycosylated both on light chain and heavy chain. Our results showed that the contents of glycosylation of IgG1-κ mAb increased in G0F and fucosylated type glycans as a group, whereas sialylated type glycans decreased, for the mAb whole protein. Overall, significant differences were observed in amounts of G0F, G1F, G0, G2FS1, and G2FS2 type glycans across all process intensification levels. G2FS2 and G2 type N-glycans were predominantly quantifiable from light chain rather than heavy chain. It may be concluded that there is a potential impact to product quality attributes of therapeutic proteins during process intensification via perfusion cell culture that needs to be assessed. Since during perfusion cell culture the product is collected throughout the duration of the process, lot allocation needs careful attention to process parameters, as PQAs are affected by the critical process parameters (CPPs). Key points • Molecular integrity may suffer with increasing process intensity. • Galactosylated and sialylated N-glycans may decrease. • Perfusion culture appears to maintain protein charge structure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA.
- Department of Chemical Engineering, University of Massachusetts Lowell, Lowell, MA, USA.
- Division of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA. chikkathur.madhavarao@fda.hhs.gov.
Zitieren
APA
Liang, G., Madhavarao, C. N., Morris, C., O'Connor, T., Ashraf, M., & Yoon, S. (2024). Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture. Applied Microbiology and Biotechnology, 108(1). https://doi.org/10.1007/s00253-024-13110-9
Vancouver
Liang G, Madhavarao CN, Morris C, O'Connor T, Ashraf M, Yoon S. Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture. Applied Microbiology and Biotechnology. 2024;108(1). doi:10.1007/s00253-024-13110-9
BibTeX
@article{Liang2024,
author = {Liang, George and Madhavarao, Chikkathur N and Morris, Caitlin and O'Connor, Thomas and Ashraf, Muhammad and Yoon, Seongkyu},
title = {Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture},
journal = {Applied Microbiology and Biotechnology},
year = {2024},
volume = {108},
number = {1},
doi = {10.1007/s00253-024-13110-9}
}
EUVIMED